Technological University Dublin

ARROW@TU Dublin
Articles

School of Food Science and Environmental
Health

2021-1

In silico and in vitro screening for potential anticancer candidates
targeting GPR120
Ajay Pal
Technological University Dublin, ajay.pal@tudublin.ie

James Curtin
TU Dublin, james.curtin@tudublin.ie

Gemma K. Kinsella
Technological University Dublin, gemma.kinsella@tudublin.ie

Follow this and additional works at: https://arrow.tudublin.ie/schfsehart
Part of the Bioinformatics Commons

Recommended Citation
Pal, A., Curtin, J. & Kinsella, G. (2021) In silico and in vitro screening for potential anticancer candidates
targeting GPR120, Bioorg Med Chem Lett, 2021 Jan 1;31:127672. doi: 10.1016/j.bmcl.2020.127672

This Article is brought to you for free and open access by
the School of Food Science and Environmental Health at
ARROW@TU Dublin. It has been accepted for inclusion in
Articles by an authorized administrator of ARROW@TU
Dublin. For more information, please contact
arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie.
This work is licensed under a Creative Commons
Attribution-Noncommercial-Share Alike 4.0 License

Bioorg. Med. Chem. Lett. 31 (2021) 127672

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier.com/locate/bmcl

In silico and in vitro screening for potential anticancer candidates
targeting GPR120
Ajay Pal a, b, c, James F. Curtin a, d, Gemma K. Kinsella a, *, e
a
b

School of Food Science and Environmental Health, College of Sciences and Health, Technological University Dublin, Dublin D07 ADY7, Ireland
Environmental Sustainability and Health Institute (ESHI), Grangegorman, Technological University Dublin, Dublin D07 H6K8, Ireland

A R T I C L E I N F O

A B S T R A C T

Keywords:
Molecular docking
Virtual screening
GPCR GPR120
FFA4 receptor
Colorectal cancer

The G-protein coupled receptor - GPR120 has recently been implicated as a novel target for colorectal cancer
(CRC) and other cancer managements. In this study, a homology model of GPR120S (short isoform) was
generated to identify potential anti-cancer compounds targeting the GPR120 receptor using a combined in silico
docking-based virtual screening (DBVS), structure–activity relationships (SAR) and in vitro screening approach.
SPECS database of synthetic chemical compounds (~350,000) was screened using the developed GPR120S
model to identify molecules binding to the orthosteric binding pocket followed by an AutoDock SMINA rigidflexible docking protocol.
The best 13 hit molecules were then tested in vitro to evaluate their cytotoxic activity against SW480 – human
CRC cell line expressing GPR120. The test compound 1 (3-(4-methylphenyl)-2-[(2-oxo-2-phenylethyl)sulfanyl]5,6-dihydrospiro(benzo[h]quinazoline-5,1′ -cyclopentane)-4(3H)-one) showed ~ 90% inhibitory effects on cell
growth with micromolar affinities (IC50 = 23.21–26.69 µM). Finally, SAR analysis of compound 1 led to the
identification of a more active compound from the SPECS database showing better efficacy during cell-based
cytotoxicity assay –5 (IC50 = 5.89–6.715 µM), while a significant reduction in cytotoxic effects of 5 was
observed in GPR120-siRNA pre-treated SW480 cells.
The GPR120S homology model generated, and SAR analysis conducted by this work discovered a potential
chemical scaffold, dihydrospiro(benzo[h]quinazoline-5,1′ -cyclopentane)-4(3H)-one, which will aid future research
on anti-cancer drug development for CRC management.

GPR120 is a member of the Class A Rhodopsin-like G-protein coupled
receptor (GPCR) family and the free-fatty acid receptors (FFAR) sub
family and exists in two homologous human isoforms (a short isoform at
361 amino acids and a long isoform at 377 amino acids).1,2 It is also
known as Free Fatty Acid 4 receptor (FFA4) – as its endogenous ligands
have been identified as poly-unsaturated long-chain free fatty acids
(PUFFA).3–5 GPR120 over-expression has been reported in colorectal
cancer (CRC) cell lines, at approximately 2–3 folds higher occurrence
than for normal colorectal cells.6 In CRC, GPR120 overexpression has
been correlated with enhanced protein expression of proangiogenic
factors such as vascular endothelial growth factors (VEGF),
cyclooxegenase-2, and interleukin-8, as well as enhanced chemotactic
activity of tumour cells.6 This increased activity has been characterised

as GPR120-induced activation of the PI3K/Akt-NF-κB signalling
pathway.6 GPR120 has also been reported to augment chemoresistance
in breast cancer treatment by cross-talk through the Akt/NF-κB
pathway.7 An extensive review by Senatorov and Moniri8 outlines the
regulating role of GPR120 in various human cancers such as breast
cancer, osteocarcinoma, melanoma prostate cancer, lung cancer,
pancreatic cancer, and CRC.8
Tumour cells are known to secrete pro-angiogenic factors9,10 and
over-expression of GPR120 in CRC cell lines might be further stimu
lating the development of tumour angiogenesis. As well, GPR120 ago
nism is reported to result in lower rate of cell proliferation and cell
migration and increased rate of apoptosis in various cancer cell lines and
animal models.8 Most of the FDA approved anti-angiogenic drugs10 are
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Fig. 1. Selected docked pose of TUG891 (binding score − 9.87591) illustrating hydrogen bond interactions with Arg99 of GPR120S and a 2D interaction map of
TUG891 in the orthosteric pocket binding pocket. The 3D images were visualized and rendered in PyMol v2.1.0.21 The 2D interaction maps were generated in BIOVIA
DS Client visualizer 2019.22

prescribed in combination with cytotoxic agents for effective CRC
treatment. As GPR120 is involved at two extreme ends of the cancer
therapeutics spectrum and tumour angiogenesis, it is of significant in
terest to develop and characterise small molecular anticancer agents
targeting GPR120. Research studies, so far, have resulted in develop
ment of few potent GPR120 agonists only, such as TUG891 (see Fig 1),
and a negative allosteric modulator, AH7614.11
Due to advances in protein engineering, the availability of GPCR
crystallographic structures in the RCSB Protein Data Bank12 has
increased and allows the collection of structural data on GPCRs for early
stage computer aided drug discovery (CADD). GPCRs crystal structure
data can also be used as the reference templates for comparative
modelling or homology modelling (HM), to predict the three dimen
sional (3D) structure of homologous GPCRs. Such in silico homology
models of GPCRs have been successfully employed in virtual screening
(VS) studies to identify lead molecules for developing therapeutic agents
acting as agonists, inverse agonists, or antagonists.13,14. This method
ology is termed structure-based virtual screening (SBVS) and more
specifically docking-based virtual screening (DBVS) is the most applied
in practice.15,16.
In recent years, in silico VS studies followed by in vitro experiments
have been successfully utilised to discover potential leads for developing
GPCR ligands.17 These in silico VS provide a faster and economical
alternative to the wet-lab high-throughput screenings.18 In addition to
VS, analysis of structure–activity relationships (SARs) can lead to the
design of potent and stable compounds by making rational structural
modifications19,20.
In this study, a GPR120 DBVS protocol was developed utilising
molecular docking with an in-house homology model in iterative com
bination with an in vitro cytotoxicity screening assay and SAR analysis,
resulting in the identification of novel compounds with anticancer

potential and predicted to act through GPR120.
Methods
VS was performed on the Irish Centre for High-End Computing
(ICHEC – www.ichec.ie) cluster. ICHEC provided CPU core units for
computational processing and data storage space. The visual analysis
and homology model building were carried out on an in-house 8 node
(Intel® Core™ i7-4790 CPU @ 3.60 GHz × 8) Linux cluster. The visual
analysis and image rendering was performed using PyMol Open-source
version 2.1.021 and Biovia DS Client visualiser 2019.22
Homology modelling
The FASTA sequences of human GPR120 short isoform, termed
GPR120S - (UniProt ID: Q5NUL3-2) was retrieved from the UniProt
database (https://www.uniprot.org Uniprot 2016). The sequence was
used for BLASTP analysis (https://blast.ncbi.nlm.nih.gov/Blast.cgi) run
against the protein databank (PDB) to identify 3D determined protein
structures according to the best multiple sequence alignment (MSA)
score generated. The human Delta-like opioid receptor PDB-ID: 4N6H
and human Orexin 2 receptor PDB-ID: 4S0V were used as template
structures. Using the multiple sequence alignment of GPR120S and the
templates, comparative 3D structural models were generated and vali
dated using MODELLER (v9.14).23 An in-house python pipeline (incor
porating MODELLER) was developed using the KNIME platform
(Konstanz Information Miner)24 to automate the process from genera
tion of 100 models using the MSA of selected templates to side-chain
rotamer optimisation using SCWRL425 and evaluation of homology
models by MODELLER’s DOPE (Discrete Optimized Protein Energy)
score function.23 The models were ranked by the DOPE statistical
2
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potential scoring models. The best models with the lowest DOPE values
were then assessed for stereochemical properties using the MolProbity
webserver26 and their phi-psi Ramachandran plot were generated by
using the PROCHECK online tool,27 validation process (unpublished
work).

− 20 ◦ C.
SW480 cells were transfected with 50 nM GPR120 (human) − 27mer
siRNA duplex (SR317391) using siTran 2.0 siRNA transfection reagent
(OriGene – www.origene.com) according to manufacturer’s instructions
after overnight seeding. Universal scrambled siRNA duplex (SR30004)
was used as negative control in transfection experiments.

Ligand library preparation

In vitro screening by cell-based cytotoxicity assay

The SPECS database (www.specs.net) of synthetic chemical com
pounds (~350,000) was retrieved and processed in Biovia Discovery
Studio’s Pipeline Pilot v9.1 from Dassault Systèmes22 to generate ste
reoisomers and tautomers, and remove compounds with molecular
weight (greater than) > 650 and (less than) < 250 Dalton. The filtered
chemical database was energy minimised using MMFF94 forcefield
(steepest descent) in the open-source OpenBabel software package (htt
p://openbabel.org/) and saved in sdf format.

Alamar blue based cytotoxicity assays were performed to determine
inhibitory effects of the test compounds. SW480 cells were seeded at
10,000, 5,000 and 2500 cells per well in 96-well plates for 24, 48 and/or
72 h drug treatment, respectively. Required dilutions of test compounds
were freshly prepared in 0.5% (v/v) DMSO growth media for cytotox
icity assays. After the treatment period, drug concentrations were
replaced with 6% (v/v) alamar blue dye solution and the cells were
incubated for 3 h under cell incubation conditions. Finally, the fluo
rescence signal was read using 560 nm excitation and 590 nm emission
filters with Varioskan LUX Multimode Microplate Reader from Ther
moFisher Scientific.
siRNA transfected cells were harvested after 24 h of transfection and
used for cytotoxicity assays as explained above.

Virtual screening and molecular docking
Molecular docking analysis was performed between the prepared
ligands and the homology model of GPR120S (unpublished work) which
was pre-processed in MGLs’ AutoDock tools (www.autodock.scripps.
edu)28 to add polar hydrogens, charges by Kollman charge and assign
torsion angles. The rigid-flexible docking protocol was followed by using
Autodock SMINA (scoring and minimization in AutoDock VINA).29 The
binding site grid box was visually defined by employing AutoDock tools’
Grid setting feature, based on the site-specific mutation study by Hudson
et al. 201430 to include residues – Arg99(TM2), Trp104 (ECL1), Phe115
(TM3), Trp207, Phe211 (TM5), Trp277 (TM6) and Phe304 (TM7),
deemed essential for ligand binding. The grid size dimensions were 40 ×
60 × 60, with the (61.822, 59.75, 46.597) point set as the centre co
ordinates of the pocket. TUG891, being a selective potent agonist of
GPR120,31 was used as the reference ligand for docking analysis.
The docked poses generated by AutoDock SMINA were rescored with
three different scoring functions, AutoDock Vina,32 NNScore 2.0 (neural
network based scoring function)33 and DLSCORE (Deep learning based
scoring function) https://github.com/sirimullalab/DLSCORE), to
calculate the consensus binding affinity score (Cscore) using Eq. (1).
AutoDock VINA and SMINA predicts the binding affinities as Gibbs free
energy (ΔG kCal/mol) while NNScore 2.0 and DLSCORE predicts the
binding affinities as pKd values34.

Statistical analysis
All data was presented as mean ± standard error of the mean (SEM).
For the analysis and graphic representation of biological experimental
IC50 values were calculated (GraphPad Prism 6 Software, La Jolla CA)
using dose–response curves for the compounds. For plotting the dos
e–response curve, a non-linear regression curve fitting method was used
where the mean positive control (50% DMSO in growth media) was
defined as 0% and the mean vehicle control (0.5% DMSO in growth
media) was defined 100%. For significance analysis, two-way analysis of
variance (ANOVA) followed by Tukey’s multiple comparison test was
performed. P < 0.05 was considered statistically significant.
Results and discussion
Homology model of GPR120
The human GPR120S receptor model was developed using the
MODELLER homology modelling tool.23 The model which scored best
(DOPE score − 41156.738) as per the MODELLER scoring function was
chosen as the final model and subjected to further energy minimization.
The α-carbon RMSD (root mean squared deviation) between the tem
plates 4N6H, 4S0V and the developed human GPR120S model is 1.386 Å
and 0.652 Å, respectively. Poor rotamers and sidechain rotations, above
the permitted range of 0.3%, were removed and replaced by SCWRL4
with the average sidechain rotamer from its backbone-dependent
rotamer library based on kernel density estimates. The comparative
analysis of the stereochemical parameters of the GPR120S model by
Molprobity webserver showed high reliability of the generated models.
The Ramachandran psi-phi evaluation showed that all helical amino
acids are located in the region favouring a right-handed α-helix with no
residues (0%) in a sterically disallowed region and 98–99% residues in
the favoured regions. The GPR120S model was embedded in a lipid
bilayer model and energy minimised (unpublished work).

Cscore = Vscore + Sscore +(− NN score )+ (− DLscore )/Number of scoring functions
(1)
where: Cscore is consensus docking score. Vscore is docking using Auto
Dock Vina’s default scoring function. Sscore is docking score using SMI
NA’s default scoring function. NNscore is docking score using NNScore
2.0 function. DLscore is docking score using DLScore function.
The ligands with a Cscore lower than − 9 were further analysed
manually using the PyMol Open-source version 2.1.021 to enlist mole
cules for phase I of the in vitro screening based on their diverse scaffold
chemistry. For phase II of in vitro screening, the chemical scaffold of the
most cytotoxic test compound (from phase I) was used for a substructure
search from the SPECS database docked pool using Discovery Studio’s
Pipeline Pilot from Dassault Systèmes 201722.
Cell culture and materials

Molecular docking of TUG891 to the GPR120S model

SW480, a human CRC cell line was cultured in RPMI1640 growth
media supplemented with 10% (v/v) Fetal Bovine Serum and incubated
at 37 ◦ C ± 1 ◦ C in a humidified atmosphere with 5% CO2. The cell
culture media and reagents were procured from Sigma-Merck, unless
otherwise mentioned. The test compounds for in vitro screening assays
were procured from SPECS (www.specs.net). A stock solution of test
compounds (20 mM) was prepared in 100% (w/v) DMSO and stored at

The docked pose of TUG891 – a potent GPR120 selective agonist,
with the receptor binding pocket is shown in Fig 1. An arginine in TM2
(Arg99) is critical for interaction between the receptor and the -COOH
group of its ligands by various studies.30,31,35,36 Six other specific resi
dues are essential for TUG891, and other GPR120 agonists binding and
interaction which are: Trp104 (ECL1), Phe115 (TM3), Trp207, Phe211
3
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SPECS_ID

VINA

NNScore

DLScore

SMINA

Cscore

AN-970/
40920574
AK-968/41925665
AO-299/
41877474
AE-848/32608035
AN-970/
40920575
AG-690/40104520
AJ-292/40857565
AN-758/
14707017
AK-968/15252756
AO-081/
14456496
AK-968/12713190
AB-131/42301549
AG-690/12137150

− 14.0799

10.6167

7.5808

− 14.0822

− 11.589

interaction) with the Arg99 side-chain at a distance of 4.32 Å and a
strong T-type (perpendicular) π-π stacking interaction between Phe115
and the second aromatic ring structure of TUG891. Other equitable
hydrophobic and van der Waals interactions were also observed to sta
bilize the docked TUG891 in the orthosteric binding pocket.

− 14.1500
− 13.3325

8.4778
9.3340

8.1736
8.2664

− 14.1543
− 13.3348

− 11.238
− 11.066

In silico virtual screening

− 13.0308
− 12.8216

9.5607
9.9850

8.3752
7.6430

− 13.0307
− 12.8253

− 10.999
− 10.818

− 13.1039
− 13.1769
− 12.5595

8.8878
8.3250
9.5580

8.1416
8.0350
7.3621

− 13.1031
− 13.1788
− 12.5586

− 10.809
− 10.678
− 10.509

− 12.5863
− 11.7869

8.3809
9.2246

8.2112
7.7837

− 12.5838
− 12.2584

− 10.441
− 10.263

− 12.3380
− 12.2715
− 12.2680

8.5407
8.4730
6.8487

7.6893
6.8798
7.0743

− 12.3375
− 12.8521
− 12.2687

− 10.226
− 10.119
− 9.614

Table 1
Virtual-HTS hit compounds from the SPECS database with scores from each
scoring function and the consensus score (Cscore).

For virtual screening, the SPECS database (www.specs.net) con
taining ~ 350,000 commercially available well-characterised and druglike molecules was screened against the GPR120S homology model.
AutoDock SMINA was used as the molecular docking algorithm and the
docked poses were rescored using an in-house consensus scoring func
tion from Equation I (see methods). The best scoring poses docked into
the receptor were manually evaluated by comparison with the docked
pose of TUG891.
The docking-based virtual screening with a score cut off set at − 9 (w.
r.t binding score of TUG891 of − 9.8) followed by a manual docking-pose
analysis resulted in 13 compounds (Table 1) being selected for the first
phase of in vitro screening through Alamar Blue cytotoxicity assay. As
per the docking evaluation, these compounds are predicted to bind to
the orthosteric binding pocket of GPR120S (see Fig 2) as well as having
similar hydrophobic and / or electrostatic interactions with one or more
of the residues reported essential for the pharmacological activity of the
receptor.
The electrostatic potential surface maps shown in Fig 2 reveal that
the GPR120S binding pocket is lined with negatively charged residues
(red colour) which can interact with ligand molecules via hydrogen
bond contacts, whereas the opening of the pocket is surrounded by
neutral or weak potential residues. Theoretically ligands with a strong

(TM5), Trp277 (TM6) and Phe304 (TM7).30 Interactions with these
seven residues were selected as the main criterion for docked binding
pose selection of TUG891.30,31 Automated protein–ligand interaction
analysis using the PLIP webserver37 identified strong noncovalent in
teractions of residues forming contacts with TUG891 docked to the
orthosteric binding pocket of GPR120S (Fig 1).
The selected docked pose for TUG891 (binding score − 9.875) had
interactions with Arg99 in all the predicted poses. The carboxylic acid of
TUG891 forms a salt bridge (hydrogen bond and attractive charge

Fig. 2. Docking simulation of 13 test molecules with surface topology of the GPR120S orthosteric binding pocket (a). Zoomed in view of the electrostatic potential
molecular surface of the orthosteric binding pocket as viewed from above (b) was calculated with APBS (Adaptive Poisson-Boltzmann Solver) plugin in PyMOL. Blue
denotes a positively charged surface; red denotes a negatively charged surface. The bound test molecules are shown as green stick models. The 3D images were
visualized and rendered in PyMol v2.1.0.21
4
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Fig. 3. a) Cytotoxicity assay of test compounds in SW480 cells which express GPR120 at three concentrations 100, 10 and 1 µM. Results from six replicates are
expressed as the mean ± Standard error. The cytotoxicity of b) Compound 1 (experimental 24 h IC50 23.21 to 26.69 µM) and; c) Compound 2 (experimental 24 h IC50
26.55 to 33.2 µM) was assayed by using SW480 cells using 9 serial dilutions from 100 µM to 0.39 µM at three different treatment time periods. Results show mean and
standard error of 5 replica samples. Results are representative of three individual experiments. Where no error bars are visible, they are obscured by the symbol.
Percent relative cell viability for all treatments were quantified and normalised to the maximal response induced by vehicle control. Data for (a) was analysed by twoway ANOVA and asterisk values denote significant differences between 100, 10 and 1 µM treatment for each compound (*P < 0.05; **P < 0.01; ***P < 0.001; ****P
< 0.0001).

positive charge should be able to enter the binding tunnel without facing
any resistance from the neutral or weakly charged residues at the
opening.38 Once the ligand enters the pocket the strong attractive
charges should stabilise the protein–ligand binding, playing an impor
tant role in the binding kinetics. Steered molecular dynamics (SMD)
studies can be insightful to further probe the binding kinetics of ligands
w.r.t the charged surfaces of binding tunnel.38,39

3a, most of the compounds (11 out of 13) displayed null to negligible
(~30%) cytotoxicity against SW480 cells at the highest tested concen
tration of 100 µM. However, two of the test compounds showed signif
icant (>90%) inhibitory effects on cell growth with micromolar
affinities (at 100 µM), reported in Fig 3a.
The two active compounds - AK-968/12713190 (compound 1) and
AG-690/40104520 (compound 2), were further tested at a wider con
centration panel to construct a dose–response curve and determine their
IC50 values (see Fig 3b, c). Both the test compounds were active in cell
line measurements with modest inhibitory activity at different treatment
times. The 24 h drug treatments indicated IC50 value of 23.21–26.69 µM
for 1 and 26.55–33.2 µM for 2.
As the Dose-response-time (DRT) can highlight the dose–response
patterns over time in pharmacological studies,40 these two test com
pounds were tested over a longer treatment times of 48 h and 72 h for

In vitro cytotoxicity assay
The selected 13 compounds from the in silico VS were evaluated for
their potential anticancer activity by an alamar blue cytotoxicity assay
(see methods) using SW480 cells expressing GPR120.6 For initial
screening, the SW480 cell-line was treated with three concentrations
(100, 10 and 1 µM) of each test compound for 72 h. As illustrated in Fig
5
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Fig. 4. 2D interaction maps of docked poses of compounds 1 and 2. The 2D interaction maps were generated in BIOVIA DS Client visualizer 2019.22

their cytotoxicity activity (see Fig 3b, c). After 48 h, the IC50 of both
compounds drops to ~50–60 µM. Similar effects over time have been
reported in another oncogenic study41 suggesting that the cells might
have developed acquired resistance to test compounds at lower con
centration after 48 h of exposure. This acquired resistance might enable
them to escape the cytostatic state and start cell proliferation which can
be traced back to the augmented chemoresistance in breast cancer
treatment through GPR120 overexpression.7 Also, the increased meta
bolic activity of cancer cells can be related to anticancer drug meta
bolism responsible for the resistance to cytotoxic agents,42,43 hence
reducing the cytotoxicity of these two compounds over time. While the
72 h experiments showed a slight decrease of 10 µM in IC50 values of
both compounds, it should be noted that the drug concentrations were
not replaced over the treatment time intervals. The decreased cell
growth or increased cytotoxic effects of these two compounds at 72 h

might be the result of a lack of nutrients and increased metabolic waste
in the culture solution.44,45
SAR/similarity search and in vitro screening of SAR compounds
The top-scoring docked poses of compounds 1 and 2 (see Fig 4)
predicted that the two molecules interact with a number of residues
reported significant for protein-ligand binding by Hudson et al 201430
and which also interacted with the selected docked pose of TUG891 (see
Fig 1) such as Ile280, Ile284, Val307. Compound 1 consists of a benzoquinazoline ring structure as the chemical scaffold with smaller benzylmethyl and benzyl substituents. The phenylalanine residue at TM3
(Phe115) shows strong π-π interactions with the main scaffold as well as
π-sulfur interactions with the sulfanyl linker (see Fig 4). While com
pound 2 consists of a 9-fluorenone as the chemical scaffold with

Table 2
SAR of Compound 1 with modified groups to determine functional potency.

Compound 1 substructure
3
4
5
6
7
8
9

1

SPECS Compound ID

-R

AL-281/36997030
AJ-292/12930007
AL-281/36997031
AG-690/12134207
AL-281/36997034
AN-512/12673388
AN-512/12674229

-C6H4Cl
-C6H4Cl
-C6H4Cl
-C6H4Cl
-C6H4Cl
-C6H4Br
-C6H4Br

Generic chemical formula
-R

2

Docking Cscore

–CH3
-C5H9
-C6H5
-C2H4-C6H5
-C6H4-O- CH3
-C6H4-CH3
2,2-(CH3)2-C5H7O

−
−
−
−
−
−
−

6

9.339
9.741
10.706
10.213
9.668
10.704
9.988

Experimental IC50 (µM)

Lipinski’s Violations

22.92
24.26
5.890
68.92
6.789
25.54
N/A

0
2
2
2
2
2
2

to 27.58
to 26.95
to 6.715
to 84.21
to 7.502
to 28.87

(MW 505; logP 4.57)
(MW 513; logP 4.03)
(MW 541; logP 4.32)
(MW 543; logP 4.38)
(MW 571; logP 4.77)
(MW 593; logP 4.5)
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to procure the selective compounds for in vitro screening. The analogues
were selected exploring the alkyl to aryl substitutions at the R2 position
and simple halobenzene susbstitutions at the R1 position connected by a
sulfanyl acetone linker keeping dihydrospiro(benzo[h]quinazoline-5,1′ cyclopentane)-4(3H)-one scaffold structure intact. Based on the docking
analysis, manual screening and the availability of compounds at SPECS,
seven compounds were tested for in vitro cytotoxicity assay in SW480
cell line as discussed above (see Fig 5a).
Based on the SAR study, the IC50 values of the new hits enable an
initial identification of the essential pharmacophore features required in
the dihydrospiro(benzo[h]quinazoline-5,1′ -cyclopentane)-4(3H)-one scaf
fold. The presence of an aromatic halogen at the sulfanyl acetone tail
exhibited an increase in potency (3, 5, 7). However, the substitution of
chloride in comparison to bromide seems to be more effective for
pharmacological activity. The drop in potency of 8 w.r.t the parent
compound (1) and 5 can be related to larger atomic size of bromine atom
compared to chlorine which can result in decreased solubility and hence
lowering the bioavailability of the compounds. Although not predicted
in molecular docking which showed similar binding scores − 10.22,
− 10.706 and − 10.704 (compounds 1, 5 and 8 respectively), the greater
size of bromine might be responsible for steric clashes with neighbour
ing residues in the binding pocket which can be further analysed by
future MD studies. Incorporation of fluoroaromatics at the sulfanyl
acetone tail may increase the solubility and hence bioavailability of
these SAR analogues as the fluorine atom is smaller in size and also
exhibit slight electronegativity which can increase the electrostatic
bonding affinity of the compounds.
Substitution of the benzo-methyl at the R2 position in the parent
structure and 8 by a smaller methyl group (3) or an aromatic sixmembered group (5) resulted in a significant increase in potency of
the analogues. The substitution of a non-aromatic cyclic group (4)
resulted in reduced activity of the parent compound (1). The addition of
a methoxy group to this aromatic ring at R2 position in 7 resulted in the
second most active compound of the SAR profiling. The quinazoline ring
linked to five or six membered aromatic ring structure at R2 position by a
single C–C bond length seems to be the optimum as when the linker
length in 5 is increase (-C-C2H4-C-), the cytotoxic activity of 6 registered
a drastic decrease from ~ 6 µM to ~ 80 µM. The total inactivity of 9 may
confirm the above inferences as it contains bromo-aromatic group at R1
position and non-aromatic cyclic ring with a longer linker at the R2
position.
SAR analysis is a state-of-the-art and precise method to explore
bioactive analogues of an active compound which may improve binding
affinity to a protein target.19,20 Of the present SAR study, analogues (5
and 7) exhibited the best cytotoxic activity. When both these compounds
were tested at 5 µM (below experimental IC50) in GPR120-silenced
SW480 cells, this cytotoxic effect of 5 was significantly suppressed in
GPR120-siRNA transfected SW480 cells (Fig 5b) while 7 showed ~10%
higher cytotoxicity levels in siRNA transfected cells. The comparative
study between GPR120-silenced and control experiments suggested that
5 exhibited cytotoxic effects through GPR120 binding while cytotoxic
activity of 7 might be through multiple targets including GPR120.
However, further in silico and in vitro validation is required to confirm
their anti-cancer potential targeting GPR120. As literature suggests that
high levels of GPR120 expression in CRC cell lines increases the cell
proliferation rate and reduces apoptosis,6 it can be hypothesized that
compound 5 and 7 inhibit GPR120 and hence increase the apoptosis
rate. A comparative study of these test compounds against a competitive
antagonist would be useful, but as mentioned earlier no GPR120 an
tagonists are available to date. AH7614 (4-Methyl-N-9H-xanthen-9-ylbenzenesulfonamide) was first reported as a GPR120 selective antago
nist by GlaxoSmithKline in 201448 but its mechanism of antagonism was
not known. Later collaborative research by the Ulven and Milligan labs
in 201749 reported that AH7614 was a negative allosteric modulator of
GPR120.
In summary, with the identification of the two most active analogues

Fig. 5. a) Cytotoxicity profile of compound 1 SAR analogues using SW480 cells
for 24-hour treatment. Results show mean and standard error of 4 replica
samples. Where no error bars are visible, they are obscured by the symbol; b)
siRNA-mediated silencing of GPR120 in SW480 cells – Compound 5 and 7 were
screened against GPR120-siRNA and scrambled-siRNA (control) transfected
SW480 cells. Results from five replicates are expressed as the mean ± standard
error, ****p < 0.0001 as indicated (ANOVA, Tukey’s multiple comparisons
test). Percent relative cell viability for all treatments were quantified and nor
malised to the maximal response induced by vehicle control.

symmetric dimeric naphthalene groups at both ends linked by an ami
nosulfonyl. The presence of dimeric naphthyl substituents showing
strong hydrophobic π-π stacked interactions at one end and simple
π-Sigma interactions at the other suggesting strong binding interactions
in the binding pocket.
The chemical scaffold of 2 is 9-fluorenone (PubChem CID: 10241)
which is actively used in preparation of antimalarial drugs, functional
polymers, and dyes.46 Of the two selected compounds, 1 was prioritized
based on the strong docking predictions with the GPR120S model, its
novelty with respect to the literature and the micromolar cytotoxic ac
tivity in CRC cell line, for SAR studies. To expand the SAR profile, the
generic chemical structure, dihydrospiro(benzo[h]quinazoline-5,1′ -cyclo
pentane)-4(3H)-one, in combination with sulfanyl acetone tail was used
as query for substructure search against the pre-processed SPECS data
base using DS pipeline pilot (Table 2).
The substructure search resulted in 16 compounds from the prescreened SPECS database. This set of compounds explored R-groups in
position R1 and R2 of the scaffold (see Table 2) in combination with in
silico ADME profiling using SwissADME (http://www.swissadme.ch/)47
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from the SAR profiling of parent compound 1 (AK-968/12713190) with
a dihydrospiro(benzo[h]quinazoline-5,1′ -cyclopentane)-4(3H)-one scaf
fold, our study has successfully identified a novel scaffold for developing
potential therapeutics for CRC management. The main scaffold can be
further enhanced focusing on the substitution and addition of key
structural groups as mentioned in the SAR study. Future studies will
confirm the role of GPR120 in the cytotoxic activity exhibited by these
compounds.
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